Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -51.43% is 27% below its 2-year average of -40.46%, around the middle of its 2-year range (-88.53%–-21.16%).
As of the fiscal period ended Tuesday, June 30, 2026. 35.81% below its 12-month average of -37.87%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -51.43%.
RETURN ON EQUITY (ROE)
-51.43%
RETURN ON EQUITY (ROE) AVG TTM
-37.87%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-35.81%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-22.43%
vs the sector median at left
CeriBell, Inc.
Market Cap
$918.97M
Return on Equity (ROE)
-51.43%
TTM Avg
-37.87%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$923.17M
Return on Equity (ROE)
-61.58%
TTM Avg
-50.64%
3Y Avg
-52.69%
5Y Avg
41.64%
Market Cap
$925.92M
Return on Equity (ROE)
-612.78%
TTM Avg
-101.05%
3Y Avg
-68.21%
5Y Avg
-52.21%
Market Cap
$936.78M
Return on Equity (ROE)
N/A
TTM Avg
80.91%
3Y Avg
80.91%
5Y Avg
80.91%
Market Cap
$912.07M
Return on Equity (ROE)
5.94%
TTM Avg
5.38%
3Y Avg
4.71%
5Y Avg
4.13%
Market Cap
$952.20M
Return on Equity (ROE)
-15.09%
TTM Avg
46.85%
3Y Avg
62.20%
5Y Avg
62.20%
Market Cap
$957.40M
Return on Equity (ROE)
-96.97%
TTM Avg
-57.21%
3Y Avg
-47.20%
5Y Avg
-49.27%
Market Cap
$887.32M
Return on Equity (ROE)
23.86%
TTM Avg
-5.16%
3Y Avg
-37.28%
5Y Avg
-22.23%
Market Cap
$887.93M
Return on Equity (ROE)
59.16%
TTM Avg
-57.78%
3Y Avg
-58.75%
5Y Avg
-57.09%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CeriBell, Inc. (CBLL) | $918.97M | -51.43% | -37.87% | N/A | N/A |
| MoonLake Immunotherapeutics (MLTX)vs › | $923.17M | -61.58% | -50.64% | -52.69% | 41.64% |
| Kura Oncology, Inc. (KURA)vs › | $925.92M | -612.78% | -101.05% | -68.21% | -52.21% |
| Seaport Therapeutics, Inc. Common Stock (SPTX)vs › | $936.78M | N/A | 80.91% | 80.91% | 80.91% |
| HealthStream, Inc. (HSTM)vs › | $912.07M | 5.94% | 5.38% | 4.71% | 4.13% |
| Aktis Oncology, Inc. (AKTS)vs › | $952.20M | -15.09% | 46.85% | 62.20% | 62.20% |
| Savara Inc. (SVRA)vs › | $957.40M | -96.97% | -57.21% | -47.20% | -49.27% |
| Bioventus Inc. (BVS)vs › | $887.32M | 23.86% | -5.16% | -37.28% | -22.23% |
| Arbutus Biopharma Corp (ABUS)vs › | $887.93M | 59.16% | -57.78% | -58.75% | -57.09% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $876.64M | -24.02% | -108.12% | -89.93% | -68.76% |
ROE
-51.4%
ROA
-39.7%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -51.43% |
| 2026-03-31 | -42.87% |
| 2025-12-31 | -34.38% |
| 2025-09-30 | -31.97% |
| 2025-06-30 | -28.70% |
| 2025-03-31 | -24.60% |
| 2024-12-31 | -21.16% |
| 2024-03-31 | -88.53% |
